100-Year-Old Drug Suramin Under Investigation As Autism Treatment
the Psychiatry Advisor take:
An antimicrobial drug that was developed by researchers at German pharmaceutical company Bayer nearly 100 years ago is being investigated as a possible treatment for autism.
The drug, suramin (Germanin), was created in 1916 for the treatment of a type of a human sleep sickness known as African trypanosomiasis that is caused by a parasite. It has also been used as a remedy for onchocerciasis, more commonly known as river blindness, which is caused by a parasitic worm.
Researchers at the University of California, San Diego School of Medicine have begun a phase I clinical trial that will recruit 20 children who are all male, between the ages of four and 17, and have been diagnosed with autism. The participants cannot have a known genetic cause or mutation, such as Fragile X syndrome, or be taking any prescription medication.
The study — which is the first to test the drug in children — will involve 10 to 12 clinical visits over three to four months for each child. Half the children will receive suramin, intravenously, as a single dose or a placebo of saline. Behavioral and medical tests will be conducted before and after treatment.
In a prior research led by Robert K. Naviaux, MD, PhD, a professor of medicine, pediatrics and pathology at the medical school, and colleagues, a single injection of suramin reversed autism symptoms in mice.
Naviaux theorizes that autism may be the result of unusual cell communication due to abnormal activation of the cell danger response, which can occur due to cells being damaged by bacteria, viruses, or chemicals such as pollutants.
Researchers will investigate whether a single dose of suramin can reverse autism symptoms. Image courtesy of Bayer HealthCare Pharmaceuticals.
Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety and efficacy of an unprecedented drug therapy for autism.
The phase 1 clinical trial, which is recruiting 20 qualifying participants, will evaluate suramin — a century-old drug still used for African sleeping sickness — as a novel treatment for children with a diagnosis of autism spectrum disorder (ASD). Previous published research by Robert K. Naviaux, MD, PhD, professor of medicine, pediatrics and pathology at UC San Diego School of Medicine, and colleagues reported that a single injection of suramin reversed symptoms of ASD in mouse models.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Efficacy of Drugs for Psychosis, Relapse Prevention for Bipolar Depression, Mania
- Cost-Effectiveness of Atomoxetine for Treating Children with ADHD
- No Evidence of Cognitive Impairment With Lisdexamfetamine Dimesylate in ADHD
- Differential Testosterone Levels in Men, Women With Schizophrenia
- Plasma Autoantibodies Possible Biomarker for Schizophrenia
- Substance-Induced Psychosis Associated With Development of Schizophrenia, Bipolar Disorder
- Neuropsychiatric Events May Be Linked to Nitrated Nucleosome Levels in Lupus
- New APA Guideline Recommendation for Treatment of Alcohol Use Disorder
- Reducing PTSD Symptoms: Propranolol Before Reactivation Therapy
- Cannabis Use Associated With Subsequent Psychotic Experiences in Adolescents
- Intervention Improves Quality of Life, Agitation in Nursing Home Patients With Dementia
- Cognitive Enhancement Therapy Beneficial for Neurocognitive Function in Autism
- The Crisis of Physician Suicides: Past and Present
- Affective Temperaments in Bipolar Have a Significant Impact on Functional, Clinical Outcomes of Mania
- Ketamine: A Promising Agent for Managing Treatment-Resistant Depression